Abstract
Background: The elastic scattering spectroscopy (ESS) device (DermaSensor Inc., Miami, FL) is a noninvasive, painless, adjunctive tool for skin cancer detection.
Objectives: To investigate the performance of the ESS device in the detection of melanoma.
Methods: A prospective, investigator-blinded, multicenter study was conducted at 8 United States (US) and 2 Australian sites. All eligible skin lesions were clinically concerning for melanoma, examined with the ESS device, subsequently biopsied according to dermatologists' standard of care, and evaluated with histopathology. A total of 311 participants with 440 lesions were enrolled, including 44 melanomas (63.6% in situ and 36.4% invasive) and 44 severely dysplastic nevi.
Results: The observed sensitivity of the ESS device for melanoma detection was 95.5% (95% CI, 84.5% to 98.8%, 42 of 44 melanomas), and the observed specificity was 32.5% (95% CI, 27.2% to 38.3%). The positive and negative predictive values were 16.0% and 98.1%, respectively.
Limitations: The device was tested in a high-risk population with lesions selected for biopsy based on clinical and dermoscopic assessments of board-certified dermatologists. Most enrolled lesions were pigmented.
Conclusion: The ESS device's high sensitivity and NPV for the detection of melanoma suggest the device may be a useful adjunctive, point-of-care tool for melanoma detection.
Publication Date
11-15-2023
Content Type
Article
PubMed ID:
Citation
Hartman, R. I., Trepanowski, N., Chang, M. S., Tepedino, K., Gianacas, C., McNiff, J. M., Fung, M., Braghiroli, N. F., & Grant-Kels, J. M. (2023). Multicenter prospective blinded melanoma detection study with a handheld elastic scattering spectroscopy device. JAAD international, 15, 24–31. https://doi.org/10.1016/j.jdin.2023.10.011
Comments
Copyright: © 2023. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY. 4.0)